C4 Therapeutics (CCCC) Operating Leases (2019 - 2025)
Historic Operating Leases for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $55.2 million.
- C4 Therapeutics' Operating Leases fell 1011.34% to $55.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.2 million, marking a year-over-year decrease of 1011.34%. This contributed to the annual value of $60.0 million for FY2024, which is 878.23% down from last year.
- Per C4 Therapeutics' latest filing, its Operating Leases stood at $55.2 million for Q3 2025, which was down 1011.34% from $56.9 million recorded in Q2 2025.
- C4 Therapeutics' 5-year Operating Leases high stood at $76.8 million for Q3 2022, and its period low was $10.9 million during Q3 2021.
- Its 5-year average for Operating Leases is $55.4 million, with a median of $62.9 million in 2024.
- As far as peak fluctuations go, C4 Therapeutics' Operating Leases skyrocketed by 60286.63% in 2022, and later crashed by 1258.32% in 2023.
- Quarter analysis of 5 years shows C4 Therapeutics' Operating Leases stood at $30.8 million in 2021, then soared by 130.59% to $71.0 million in 2022, then dropped by 7.35% to $65.8 million in 2023, then dropped by 8.78% to $60.0 million in 2024, then dropped by 7.89% to $55.2 million in 2025.
- Its last three reported values are $55.2 million in Q3 2025, $56.9 million for Q2 2025, and $58.4 million during Q1 2025.